B
Belal Ahmad
Researcher at London Health Sciences Centre
Publications - 39
Citations - 2726
Belal Ahmad is an academic researcher from London Health Sciences Centre. The author has contributed to research in topics: SABR volatility model & Radiation therapy. The author has an hindex of 14, co-authored 35 publications receiving 1416 citations. Previous affiliations of Belal Ahmad include University of Western Ontario & University of Miami.
Papers
More filters
Journal ArticleDOI
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
David A. Palma,Robert Olson,Stephen Harrow,Stewart Gaede,Alexander V. Louie,Cornelis J.A. Haasbeek,Liam Mulroy,Michael Lock,George Rodrigues,Brian Yaremko,Devin Schellenberg,Belal Ahmad,Gwendolyn H.M.J. Griffioen,Sashendra Senthi,Anand Swaminath,Neil Kopek,Mitchell Liu,Karen Moore,S. Currie,Glenn Bauman,Andrew Warner,Suresh Senan +21 more
TL;DR: SABR was associated with an improvement in overall survival, meeting the primary endpoint of this trial, but three (4·5%) of 66 patients in the SABR group had treatment-related death.
Journal ArticleDOI
Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial.
David A. Palma,Robert Olson,Stephen Harrow,Stewart Gaede,Alexander V. Louie,Cornelis J.A. Haasbeek,Liam Mulroy,Michael Lock,George Rodrigues,Brian Yaremko,Devin Schellenberg,Belal Ahmad,Sashendra Senthi,Anand Swaminath,Neil Kopek,Mitchell Liu,Karen Moore,S. Currie,Roel Schlijper,Glenn Bauman,Joanna Laba,X. Melody Qu,Andrew Warner,Suresh Senan +23 more
TL;DR: With extended follow-up, the impact of SABR on OS was larger in magnitude than in the initial analysis and durable over time and there were no new safety signals, and S ABR had no detrimental impact on QOL.
Posted ContentDOI
Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
David A. Palma,Robert Olson,Stephen Harrow,Stewart Gaede,Alexander V. Louie,Cornelis J.A. Haasbeek,Liam Mulroy,Michael Lock,George Rodrigues,Brian Yaremko,Devin Schellenberg,Belal Ahmad,Sashendra Senthi,Anand Swaminath,Neil Kopek,Mitchell Liu,Karen Moore,S. Currie,Roel Schlijper,Glenn Bauman,Joanna Laba,X. Melody Qu,Andrew Warner,Suresh Senan +23 more
TL;DR: With extended follow-up, the impact of SABR on OS was larger in magnitude than in the initial analysis, and durable over time, and there were no new safety signals, and S ABR had no detrimental impact on QOL.
Journal ArticleDOI
Inter-observer and intra-observer reliability for lung cancer target volume delineation in the 4D-CT era
Alexander V. Louie,George Rodrigues,Jason Olsthoorn,David A. Palma,Edward Yu,Brian Yaremko,Belal Ahmad,I. Aivas,Stewart Gaede +8 more
TL;DR: Variability in TVD is a major source of error in 4D-CT treatment planning and development of measures to reduce inter-observer and intra-ob server TVD variability are necessary in order to deliver high quality radiotherapy.
Journal ArticleDOI
Stereotactic Ablative Radiation Therapy for the Comprehensive Treatment of Oligometastatic Tumors (SABR-COMET): Results of a Randomized Trial
David A. Palma,Robert Olson,Stephen Harrow,Stewart Gaede,Alexander V. Louie,Cornelis J.A. Haasbeek,L. Mulroy,Michael Lock,G. Rodrigues,Brian Yaremko,D. Schellenberg,Belal Ahmad,Gwendolyn H.M.J. Griffioen,S. Senthi,M. Liu,Karen Moore,S. Currie,Glenn Bauman,Andrew Warner,Suresh Senan +19 more